Increasing HPV vaccination coverage in Switzerland: a return-on-investment analysis

Background: Vaccines are the most cost-effective intervention in public health as they prevent the spread of highly contagious infectious diseases. Because of vaccine implementation and high coverage, Measles was eradicated in 2000, however the recent reappearance of measles in the United States, Europe and globally is alarming. The resurgence of Measles, Diphtheria and Mumps is due to a reduction in vaccine coverage and herd immunity. Vaccine hesitant parents, antivaxxers, and fake news on vaccines are driving the surge in those infectious diseases. The World Health Organization issued the Global Vaccine and Immunization Action Plan to reiterate the importance of vaccine implementation and coverage for several vaccine-preventable infectious diseases in the world. Qatar is preparing for the upcoming FIFA World Cup 2022 therefore maintaining high vaccine coverage, which is critical in preventing infectious diseases spreading during such mass gathering. Methods: Literature search for vaccine coverage rates, resurgence of vaccine preventable infectious diseases and risks of mass gatherings. Results: Seventeen infectious diseases are currently vaccine-preventable. The cost-effectiveness of vaccine is documented as it is estimated for each dollar spent on vaccines, 10 dollars are saved in disease treatment. A drop in vaccine coverage rates to under 90% lead to the resurgence of measles. Vaccine coverage rate in Qatar is currently at 95% which is one of the highest in the world. Qatar must maintain this high coverage rate to prevent any measles outbreaks during mass gatherings. The planned World Cup event will take place from November 21 till December 18 2022, which is the peak for seasonal influenza. In preparedness for this major event, Qatar should encourage residents and visitors to be vaccinated not just against measles and seasonal influenza, but also hepatitis and meningitis. Conclusion: Maintaining 95% vaccine coverage rate is critical for preventing the resurgence of vaccine-preventable infectious diseases during the World Cup mass gathering in Qatar.

Objectives: Italy was the first European country to introduce universal vaccination of adolescents, for both males and females, against Human Papilloma Virus (HPV) starting in 2017 with the NIP 2017–2019′s release. However, vaccine coverage rates (VCRs) among adolescents have shown a precarious take-off since the NIP’s release, and this situation worsened due to the impact of the COVID-19 pandemic in 2020. The aim of this work is to estimate the epidemiological and economic impact of drops in VCRs due to the pandemic on those generations that missed the vaccination appointment and to discuss alternative scenarios in light of the national data. Methods: Through an analysis of the official ministerial HPV vaccination reports, a model was developed to estimate the number of 12-year-old males and females who were not vaccinated against HPV during the period 2017–2021. Based on previously published models that estimate the incidence and the economic impact of HPV-related diseases in Italy, a new model was developed to estimate the impact of the aggregated HPV VCRs achieved in Italy between 2017 and 2021. Results: Overall, in 2021, 723,375 girls and 1,011,906 boys born between 2005 and 2009 were not vaccinated against HPV in Italy (42% and 52% of these cohorts, respectively). As compared with the 95% target provided by the Italian NIP, between 505,000 and 634,000 girls will not be protected against a large number of HPV-related diseases. For boys, the number of the unvaccinated population compared to the applicable target is over 615,000 in the ‘best case scenario’ and over 749,000 in the ‘worst case scenario’. Overall, between 1.1 and 1.3 million young adolescents born between 2005 and 2009 will not be protected against HPV-related diseases over their lifetime with expected lifetime costs of non-vaccination that will be over EUR 905 million. If the 95% optimal VCRs were achieved, the model estimates a cost reduction equal to EUR 529 million, the net of the costs incurred to implement the vaccination program. Conclusion: Suboptimal vaccination coverage represents a missed opportunity, not only because of the increased burden of HPV-related diseases, but also in terms of economic loss. Thus, reaching national HPV immunization goals is a public health priority.

Immune Response 2019 : Factors influencing intention to obtain the HPV vaccine among a population of universitywomen in morocco - Dr. Aicha yacouti â University of Hassan

HPV vaccines in Brazil and the world

Measles is a highly transmissible viral infection that may lead to serious illness, lifelong complications, and death. As there is no animal reservoir for measles, measles resurgence is due to human movement of viremic persons. Therefore, some have blamed the enormous migration into Europe in the past 5 years for the measles resurgence in this region. We set out to determine the main driver for measles resurgence in Europe by assessing vaccine coverage rates and economic status in European countries, number of migrants, and travel volumes. Data on measles vaccine coverage rates with two vaccine doses of measles, mumps and rubella (MMR) [Measles Containing Vaccine (MCV)2] and total number of measles cases in 2017 for Europe, including Eastern European countries, were obtained, in addition to Gross Domestic Product (GDP), and number of migrants and tourist arrivals. The outcome measured, incidence of measles per 100,000, was log transformed and subsequently analyzed using multiple linear regression, along with predictor variables: number of international migrants, GDP per capita, tourist arrivals, and vaccine coverage. The final model was interpreted by exponentiating the regression coefficients. Incidence of measles was highest in Romania (46.1/100,000), followed by Ukraine (10.8/100,000) and Greece (8.7/100,000). MCV2 coverage in these countries is less than 84%, with lowest coverage rate (75%) reported in Romania. Only vaccine coverage appears to be the significant predictor in the model (p < 0.001) for incidence of measles even after adjusting for international migrants, international tourist arrivals, and GDP per capita. With one unit increase in vaccination coverage, the incidence of measles decreased by 18% [95% confidence interval (CI): 10–25]. Our results showed that number of migrants and international tourist arrivals into any of the European countries were not the drivers for increased measles cases. Countries with high vaccine coverage rates regardless of economic status did not experience a resurgence of measles, even if the number of migrants or incoming travellers was high. The statistically significant sole driver was vaccine coverage rates. These analyses reemphasize the importance of strategies to improve national measles vaccination to achieve coverage greater than 95%.

The Viability of Using Alternative Sites to Increase Rates of Adolescent Vaccination (or: “A Rising Tide Floats All Boats”)

Surveillance of influenza in Apulia, Italy, 1999–2000, 2000–2001, 2001–2002, and 2002–2003 seasons

‘Nudge’‐based social norms messages conveying high population influenza vaccination coverage levels can encourage vaccination due to bandwagoning effects but also discourage vaccination due to free‐riding effects on low risk of infection, making their impact on vaccination uptake ambiguous. We develop a theoretical framework to capture heterogeneity around vaccination behaviors, and empirically measure the causal effects of different messages about vaccination coverage rates on four self‐reported and behavioral vaccination intention measures. In an online experiment, N = 1365 UK adults are randomly assigned to one of seven treatment groups with different messages about their social environment's coverage rate (varied between 10% and 95%), or a control group with no message. We find that treated groups have significantly greater vaccination intention than the control. Treatment effects increase with the coverage rate up to a 75% level, consistent with a bandwagoning effect. For coverage rates above 75%, the treatment effects, albeit still positive, stop increasing and remain flat (or even decline). Our results suggest that, at higher coverage rates, free‐riding behavior may partially crowd out bandwagoning effects of coverage rate messages. We also find significant heterogeneity of these effects depending on the individual perceptions of risks of infection and of the coverage rates.

To analyze the vaccination coverage and abandonment rates among children under two years old in Brazil, from 2015 to 2021. A time-series ecological study. The dependent variables of the research were "vaccination coverage" and "abandonment rate", both assessed by Brazilian region. The data were extracted in July 2022 from the Information System of the National Immunization Program. The Prais-Winsten technique was used for the trend analysis, with the aid of the STATA 16.0 software. The mean vaccination coverage in Brazil was 76.96%, with a decreasing trend during the period (Annual Percent Change=-5.12; confidence interval - CI95% -7.81; -2.34); in 2015, the rate was 88.85% and it dropped to 62.35% in 2021. In turn, the overall abandonment rate was 24.00% in 2015 and 9.01% in 2021, with a mean of 10.48% and a stationary trend (Annual Percentage Change=-9.54; CI95% -22.92; 6.12). In 2021, all the vaccines presented coverage values below 74.00% in the country. The vaccination coverage rate trend among children under two years old was stationary or decreasing for all the immunobiologicals in all Brazilian regions, with the exception of yellow fever in the South and Southeast regions. There was an increase in the abandonment rate trend for the Meningococcal C vaccine in the country and, specifically in relation to the regions, for BCG in the North, Northeast, and Midwest and for Meningococcal C in the North and Northeast.

ABSTRACTWe reviewed intervention studies designed to increase human papillomavirus (HPV) vaccination coverage to further understand the impact interventions can have on HPV vaccination coverage. We searched 5 databases for intervention studies published from June 2006 to May 2015. Studies were included if they quantitatively measured HPV vaccination coverage as an outcome and were conducted in the United States. We abstracted outcomes, methods, and results from each study and classified by type of intervention conducted. Findings from 34 studies suggest many types of intervention strategies can increase HPV vaccination coverage in different settings, and with modest cost. Interventions were effective especially when implemented in combination at both provider and community levels. However, not all interventions showed significant effects on coverage. More research is needed to identify the best methods for widespread implementation of effective strategies.

Relevance. Pneumococcal infection remains one of the most significant health problems worldwide. Vaccination of adults against it has been carried out in the Russian Federation for over 10 years. During this time, more than 9 million people have been vaccinated. However, data on the level of coverage among adults of certain risk categories are not routinely collected. Our study in 2019 showed that it was low in most groups. Given the significant increase in the volume of vaccination over the past five years, it seems appropriate to conduct a study to assess changes in the level of coverage.Aim. To study the level of vaccination coverage against pneumococcal infection in adult risk groups in the Russian Federation.Materials and methods. An observational descriptive retrospective epidemiological study was conducted. Information on the number and contingents of people vaccinated against pneumococcal infection was collected by sending a request to the executive authorities of the constituent entities of the Russian Federation in the field of healthcare. The depth of data collection was 8 years (from 2015 to 2023 inclusive), information was received from 74 out of 89 regions. In addition, federal statistical observation forms were used: No. 5 «Information on preventive vaccinations» and No. 6 «Information on the contingents of children and adults vaccinated against infectious diseases», data from the Unified Interdepartmental Information and Statistical System. The results obtained were compared with the indicators obtained in the 2019 study, which was conducted according to a similar design. The analysis was carried out using descriptive statistics methods.Results. The coverage rate of vaccination against pneumococcal infection among the adult population in the Russian Federation increased from 1.5% in 2018 to 7.7% in 2023. The most significant coverage rates were achieved among persons subject to conscription for military service (78.5%) and persons over 60 years old, living in residential care facilities (87.7%). By 2023, vaccination coverage has increased among the following risk categories: individuals with chronic bronchopulmonary diseases (from 15.1% in 2018 to 47.9% in 2023), chronic heart diseases (from 3.8% to 17.0%), patients with endocrine diseases (from 1.1% to 17.6%), liver diseases (from 4.0% to 12.0%), healthcare workers (from 4.9% to 19.7%), school and preschool employees (from 3.1% to 12.9%), employees of residential care facilities (homes for elderly, nursing homes, ect.) (from 0.1% to 26.9%), the elderly population as a whole (from 1.4% to 12.7%), and working-age men (from 1.4% to 7.0%). There was virtually no increase in coverage among all groups of immunocompromised patients (1.0% in 2018, 6.2% in 2023), the working population with risk factors harmful to the respiratory system (0.9% in 2018, 5.0% in 2023), workers in the oil and gas and chemical industries (1.3% in 2018, 1.8% in 2023).Conclusion. The obtained results indicate the need to develop a strategy of measures to promote increased vaccination coverage in risk groups that are insufficiently covered by vaccination against pneumococcal infection.

Background: There is a need to better understand HPV vaccination (HPVv) implementation in WHO Europe Region (WHO/ER), including recommendations, funding, and vaccination coverage rates (VCR). Methods: A targeted literature review (up to 31 January 2020) was conducted using national health ministry websites, WHO database, and published studies from WHO/ER countries (n = 53). HPVv recommendations and funding data (target age, gender, schedule, setting, target and monitored VCR) for primary and catch-up cohorts were collected. Results: National recommendations for HPVv exist in 46/53 (87%) countries, of which 38 (83%), 2 (4%), and 6 (13%) countries provided full, partial, or no funding, respectively, for the primary cohort. Fully or partially funded HPVv was provided for girls only in 25/53 (47%) countries and for both boys and girls in 15/53 (28%) countries. HPVv catch-up was fully or partially funded in 14/53 (26%) countries. Among 40 countries with a national immunization program (NIP), monitored VCRs ranged from 4.3% to 99% (n = 30). Of the 10 countries reporting VCR targets, only Portugal exceeded its target. Conclusion: Of the 53 WHO/ER countries, 40 have funded HPVv NIPs, among which 30 report VCRs. Additional efforts are required to ensure HPVv NIPs are fully funded and high VCRs maintained.

Objective To determine the genotypes of human papillomavirus (HPV) and to estimate their correlations with recurrence of perianal and anal condyloma acuminatum (CA) among men who have sex with men (MSM) in Shanghai.Methods Tissue specimens were obtained from the lesions of perianal or anal CA in 57 MSM.Flow-through hybridization and gene chip were used to determine the genotypes of HPV in these specimens.Follow-up was carried out to observe the recurrence of CA in these patients after CO2 laser treatment.Results Of the 57 specimens,56 (98.2％) were positive for HPV,and a total of 11 HPV subtypes were identified.The predominant genotypes were HPV 11 (42 cases,75％ ) and HPV 6 (30 cases,53.6％),sequentially followed by HPV 16 (8 cases,14.3％),HPV 18 (4 cases,7.1％),HPV 33 (2 cases,3.6％),HPV 59(2 cases,3.6％),HPV cp8304 (2 cases,3.6％),HPV 31 (1 case,1.8％) and HPV 35 (1 case,1.8％).Of the HPV-positive specimens,64.3％ (36/56) harbored low risk HPV types (11 and/or 6),and 35.7 ％ (20/56) harbored high risk HPV types.Among the 20 specimens positive for high risk HPV,17 (85％) harbored both low risk- and high risk-HPV genotypes.During the 6-month follow-up after CO2 laser treatment,recurrence was observed in 95％ of patients with high risk HPV and 66.7％ of patients with low risk HPV (P ＜ 0.05).Conclusions Among MSM with perianal and anal CA in Shanghai,the predominant genotypes of HPV are low risk types 11 and 6; high risk HPV infection is usually complicated by low risk HPV infection; the recurrence of CA is higher in patients with high risk HPV than in those with low risk HPV. Key words: Condylomata acuminata; Human papillomavirus; Homosexuality; Male

Background Panama implemented two-dose universal varicella vaccination (UVV) in 2018. First-dose vaccination coverage rates (VCRs) declined from 91% (2018) to 70% (2021) during the COVID-19 pandemic. We quantified the clinical and economic impact of increasing UVV VCRs over a 10-year time horizon. Methods A previously published age-structured dynamic transmission model was adapted to Panama using country-specific demographic, healthcare resource use, cost, and epidemiological data or comparable proxy. Four UVV strategies (1st dose: 15 months; 2nd dose: 4 years) were evaluated, with 1st dose VCR assumed to be (A) 70% (status quo), (B) 80%, (C) 90%, and (D) 95% for the strategies A-D (Table 1). Second dose VCR was assumed to be 50% of first dose VCR. Outcomes were evaluated over a 10-year time horizon (2022-2031) and included cumulative varicella cases, outpatient cases, hospitalizations, deaths, payer (direct) costs, and societal (direct and indirect) costs. Costs were reported in 2023 USD with 3% annual discounting. Results Under the status quo (strategy A), we estimated 232,381 cumulative varicella cases, 159,123 outpatient cases, and 7,320 hospitalizations over 10 years, resulting in total payer and societal costs of $29,335,329 and $36,893,235, respectively. Increasing 1st dose/2nd dose VCR from 70%/35% (Strategy A) to 80%/40% (Strategy B) will avert approximately 3.6% of varicella cases, 4% of hospitalizations, and 1.8% of deaths. Increasing VCR to 90%/45% (Strategy C) will avert 6.8% of all cases, 7.7% of hospitalizations, and 3.5% of deaths compared to reference Strategy A. The impact of increasing VCRs to 95%/47.5% (Strategy D) resulted in a further reduction in varicella cases by about 20% more than Strategy C. Strategies B-D increased payer costs by 2%-6% ($0.02-$0.04 per person per year [PPPY]) and societal costs by 1%-4% ($0.01-$0.03 PPPY) over the 10-year time horizon versus reference strategy A (Figure 1). Conclusion Increasing UVV VCRs compared to the status quo will result in improved clinical outcomes with marginal increases in payer and societal costs. Disclosures Colleen Burgess, MS, Merck &amp; Co., Inc., Rahway, NJ, USA: Contractor Salome Samant, MBBS, MPH, Merck &amp; Co., Inc., Rahway, NJ, USA: Employee- earned salary and own stock|Merck &amp; Co., Inc., Rahway, NJ, USA: Stocks/Bonds (Public Company) Luciana Hirata, PhD, Merck &amp; Co., Inc., Rahway, NJ, USA.: I am an employee of MSD subsidiary of Merck &amp; Co., Inc., Rahway, NJ, USA. and may hold stock or stock options in Merck &amp; Co., Inc. Cintia I. Parellada, MD, PhD, Merck &amp; Co., Inc: Employee|Merck &amp; Co., Inc: Stocks/Bonds (Private Company) Manjiri D. Pawaskar, PhD, merck: employee|merck: Stocks/Bonds (Public Company) John C. Lang, PhD, MSc, MSc, BSc, Merck &amp; Co., Inc.: Stocks/Bonds (Private Company)|Merck Canada Inc.: Employee

HPV Genotype Detection Using Hybrid Capture Sample Preparation Combined with Whole Genome Amplification and Multiplex Detection with Luminex XMAP